NCT06438627View on ClinicalTrials.gov

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2029

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

TPC combined with Apatinib and Camrelizumab

Nab-Paclitaxel, Cisplatin, and Capecitabine Chemotherapy Combined With Apatinib and Camrelizumab

DRUG

GP Combined With Camrelizumab

Gemcitabine, Cisplatin regimen Combined With Camrelizumab

Trial Locations (2)

510060

RECRUITING

SunYat-senU, Guangzhou

Unknown

RECRUITING

Sun Yat sen Memorial Hospital, Guangzhou

All Listed Sponsors
lead

XIANG YANQUN

OTHER